Atomoxetine;Methylphenidate;Lisdexamfetamine shortage — EU supply status & alternatives

Atomoxetine;Methylphenidate;Lisdexamfetamine

—

In supply · Australia

ADHD medicines

In supply · 🇦🇺 Australia · short in🌐 EU🇺🇸 US

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Atomoxetine;Methylphenidate;Lisdexamfetamine

Brand names	ADHD medicines

Therapeutic category	Auto-created by European Medicines Agency — Medicines Shortages scraper

Controlled substance	No

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Recalls official enforcement reports

🇺🇸

Atomoxetine Hcl Active Pharmaceutical Ingredient Packaged In

Attix Pharmaceuticals · Nov 2014

Class IIdetails ↗

🇺🇸

Atomoxetine Hcl

Aidapak Services, LLC · July 2013

Class IIdetails ↗

🇺🇸

Atomoxetine Hcl

Aidapak Services, LLC · July 2013

Class IIdetails ↗

🇺🇸

Atomoxetine Hcl

Aidapak Services, LLC · July 2013

Class IIdetails ↗

Verified timeline regulator events

🇺🇸 30 Apr 2026

high reported

🌐 19 Feb 2025

Shortage resolved

🇺🇸 29 Jan 2025

high reported

🌐 4 Nov 2024

Shortage resolved

🌐 18 Dec 2023

high reported

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.